Stay updated on Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial page.

Latest updates to the Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial page
- Check7 days agoChange DetectedThe page's revision label was updated from v3.6.4 to v3.6.5, signaling a newer version of the page rather than changes to study details.SummaryDifference0.1%

- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedUpdated the page revision label from v3.6.3 to v3.6.4, signaling a minor metadata update to the page. This change does not alter study details, eligibility, endpoints, or results.SummaryDifference0.1%

- Check28 days agoNo Change Detected
- Check42 days agoChange DetectedThe page's revision label was updated from v3.6.2 to v3.6.3, indicating a backend/frontend update. There is no evident change to the study details, enrollment criteria, or other user-facing content.SummaryDifference0.1%

- Check49 days agoChange DetectedRevision label updated from v3.6.0 to v3.6.2 on the page, indicating a minor document update.SummaryDifference0.1%

- Check63 days agoChange DetectedEnrollment status updated to indicate recruitment has ended. The page also adds new help/navigation sections (How to Read a Study Record, Common Questions, How to Join a Study) and updates the Intervention/Treatment header formatting, with the revision label changed to v3.6.0.SummaryDifference0.5%

- Check70 days agoChange DetectedRevision: v3.5.5 was added and Revision: v3.5.4 was removed, indicating the page's revision tag was updated. This reflects a new revision deployment affecting the page's metadata rather than its content.SummaryDifference0.1%

Stay in the know with updates to Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial page.